Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant

Vaccine

Volumn 27, Issue 18, 2009, Pages 2499-2505

  Cardona, P J ^a,d   Asensio, J Gonzalo ^b,d   Arbues A ^b,d   Otal, I ^b,d   Lafoz, C ^b,d   Gil, O ^a,d   Caceres, N ^a,d   Ausina, V ^a,d   Gicquel, B ^c   Martin, C ^b,d  

^a Germans Trias i Pujol Foundation   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c INSTITUT PASTEUR   (France)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Attenuated vaccines; BCG; Safety

Indexed keywords

BCG VACCINE; ETHAMBUTOL; ISONIAZID; LIVE VACCINE; PHOP PROTEIN; RIFAMPICIN; SO2 VACCINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; GUINEA PIG; HISTOPATHOLOGY; INOCULATION; LUNG INFILTRATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SHIGELLA SONNEI; SURVIVAL RATE; TUBERCULOSIS;

ANIMALS; BACTERIAL PROTEINS; FEMALE; GUINEA PIGS; MICE; MICE, INBRED C57BL; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED;

EID: 62749159694     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.060     Document Type: Article

References (36)

1. Daniel T.M. Leon Charles Albert Calmette and BCG vaccine. Int J Tuberc Lung Dis 9 9 (2005) 944-945
2. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 5419 (1999) 1520-1523
3. Young D., and Dye C. The development and impact of tuberculosis vaccines. Cell 124 4 (2006) 683-687
4. Fine P.E. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11 Suppl 2 (1989) S353-S359
5. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 8986 (1995) 1339-1345
6. Harboe M., Oettinger T., Wiker H.G., Rosenkrands I., and Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 64 1 (1996) 16-22
7. Brodin P., Majlessi L., Brosch R., Smith D., Bancroft G., Clark S., et al. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 190 1 (2004) 115-122
8. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9 5 (2003) 533-539
9. Orme I.M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun 56 12 (1988) 3310-3312
10. Orme I.M. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24 1 (2006) 2-19
11. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 17 (2006) 3408-3419
12. Perez E., Samper S., Bordas Y., Guilhot C., Gicquel B., and Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 41 1 (2001) 179-187
13. Frigui W., Bottai D., Majlessi L., Monot M., Josselin E., Brodin P., et al. Control of M. tuberculosis ESAT-6 Secretion and Specific T Cell Recognition by PhoP. PLoS Pathog 4 2 (2008) e33
14. Chesne-Seck M.L., Barilone N., Boudou F., Gonzalo Asensio J., Kolattukudy P.E., Martin C., et al. A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra. J Bacteriol 190 4 (2008) 1329-1334
15. Gonzalo-Asensio J., Soto C.Y., Arbues A., Sancho J., del Carmen Menendez M., Garcia M.J., et al. The Mycobacterium tuberculosis phoPR operon is positively autoregulated in the virulent strain H37Rv. J Bacteriol 190 21 (2008) 7068-7078
16. Gonzalo Asensio J., Maia C., Ferrer N.L., Barilone N., Laval F., Soto C.Y., et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem 281 3 (2006) 1313-1316
17. Gonzalo-Asensio J., Mostowy S., Harders-Westerveen J., Huygen K., Hernandez-Pando R., Thole J., et al. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS ONE 3 10 (2008) e3496
18. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 85 1-2 (2005) 29-38
19. Palomino J.C., Martin A., Camacho M., Guerra H., Swings J., and Portaels F. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46 8 (2002) 2720-2722
20. Vordermeier H.M., Chambers M.A., Cockle P.J., Whelan A.O., Simmons J., and Hewinson R.G. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect Immun 70 6 (2002) 3026-3032
21. Brennan M.J. The tuberculosis vaccine challenge. Tuberculosis (Edinb) 85 1-2 (2005) 7-12
22. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 6 (2006) 469-476
23. Kamath A.T., Fruth U., Brennan M.J., Dobbelaer R., Hubrechts P., Ho M.M., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 29 (2005) 3753-3761
24. Hinchey J., Lee S., Jeon B.Y., Basaraba R.J., Venkataswamy M.M., Chen B., et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117 8 (2007) 2279-2288
25. Rivero A., Marquez M., Santos J., Pinedo A., Sanchez M.A., Esteve A., et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis 32 1 (2001) 159-161
26. Soto C.Y., Menendez M.C., Perez E., Samper S., Gomez A.B., Garcia M.J., et al. IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J Clin Microbiol 42 1 (2004) 212-219
27. Samper S., and Martin C. Spread of extensively drug-resistant tuberculosis. Emerg Infect Dis 13 4 (2007) 647-648
28. Ludwiczak P., Gilleron M., Bordat Y., Martin C., Gicquel B., and Puzo G. Mycobacterium tuberculosis phoP mutant: lipoarabinomannan molecular structure. Microbiology 148 Pt 10 (2002) 3029-3037
29. Elhay M.J., Oettinger T., and Andersen P. Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the guinea pig. Infect Immun 66 7 (1998) 3454-3456
30. Baldwin S.L., D'Souza C., Roberts A.D., Kelly B.P., Frank A.A., Lui M.A., et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66 6 (1998) 2951-2959
31. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., and Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 68 3 (2000) 1706-1709
32. Taylor J.L., Turner O.C., Basaraba R.J., Belisle J.T., Huygen K., and Orme I.M. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 71 4 (2003) 2192-2198
33. Derrick S.C., Dheenadhayalan V., Yang A., Kolibab K., and Morris S.L. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. Vaccine (2008)
34. Cardona P.J., Amat I., Gordillo S., Arcos V., Guirado E., Diaz J., et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23 11 (2005) 1393-1398
35. Cardona P., and Amat I. Origin and Development of RUTI, a New Therapeutic Vaccine Against Mycobacterium tuberculosis Infection. Arch Bronconeumol 42 1 (2006) 25-32
36. Asensio J.A., Arbues A., Perez E., Gicquel B., and Martin C. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 8 2 (2008) 201-211